Please assess the completion status of the following clinical trial:

Trial Title: Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Subject has undergone previous nephrectomy.~* Subject has received at least 2 cycles (12 weeks) of treatment with sunitinib for RCC and stopped therapy due to progressive disease within 100 days prior to screening.~* Subject has measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST.~* ECOG Performance Score of 0-1.~* No history of another active cancer within the past 5 years.Life expectancy of at least 4 months.~* Willing to take adequate measures to prevent pregnancy.~Exclusion Criteria~* Subject has received anti-cancer therapy within 21 days or within a period defined by 5 half lives, whichever is shorter, prior to study drug administration.~* Subject has untreated brain or meningeal metastases.~* Subject has received a tyrosine kinase inhibitor (TKI) other than sunitinib or sorafenib.~* Prior use of Avastin is allowed.~* The subject is receiving therapeutic anticoagulation therapy.~* The subject has a history of/or currently exhibits clinically significant cancer related events of bleeding (e.g., hematuria, hemoptysis).~* The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (BP) \> 100 mmHg; or systolic blood pressure (BP) \> 150 mmHg.~* The subject has a history of myocardial infarction within 6 months of Study Day 1.~* The subject has a documented left ventricular (LV) Ejection Fraction \< 50%.~* The subject has known autoimmune disease with renal involvement (eg, Lupus).~* Female subjects who are pregnant or breast feeding.~* Subject is receiving anti-retroviral therapy for HIV.~* Subject has a clinically significant uncontrolled condition(s) including but not limited to:~  * active uncontrolled infection,~ * Class III or IV heart failure as defined by the New York Heart Association functional classification system,~ * unstable angina pectoris or cardiac arrhythmia,~ * history of adrenal insufficiency,~ * psychiatric illness/social situation that would limit compliance with study requirements;~ * Active, ulcerative colitis, Crohn's disease, celiadisease or any other conditions that interfere with absorption.~ * Subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): One oral dose daily

Based on this trial design, predict the completion outcome and termination type (if applicable).